3-benzyloxy-6-methyl-pyran-4(1H)-one-2-carboxy-(N-methyl)-amide | 216581-52-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-benzyloxy-6-methyl-pyran-4(1H)-one-2-carboxy-(N-methyl)-amide
• 英文别名: 3-benzyloxy-6-methylpyran-4(1H)-one-2-carboxy-(N-methyl)amide；3-benzyloxy-6-methyl-4-oxo-4H-pyran-2-carboxylic acid methylamide；3-Benzyloxy-6-methyl-4(1H)-pyranone2-carboxy-(N-methyl)-amide；N,6-dimethyl-4-oxo-3-phenylmethoxypyran-2-carboxamide
• CAS: 216581-52-1
• 化学式: C₁₅H₁₅NO₄
• 分子量: 273.288
• InChiKey: HEBYPXKUBSBAEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-6-methyl-pyran-4(1H)-one-2-carboxy-(N-methyl)-amide 在 5%-palladium/activated carbon 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 1,6-dimethyl-3-hydroxypyridin-4(1H)-one-2-carboxy-(N-methyl)-amide
  参考文献：
  名称：

  Orally active iron (III) chelators

  摘要：

  提供一种化合物，其为一种新颖的3-羟基吡啶-4-酮化合物，其化学式为I，其中R为氢或在体内代谢中被去除以提供游离羟基化合物的基团，R1为脂肪烃基团或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6芳基氧基或C7-10芳基烷氧基所取代的脂肪烃基团，R3从氢和C1-6烷基中选择；R4从氢、C1-6烷基和如R2所述的基团中选择；其中R2从以下基团中选择：—CONH—R5 (i)—CH2NHCO—R5 (ii)—SO2NH—R5 (iii)—CH2NHSO2—R5 (iv)—CR6R6OR7 (v)—CONHCOR5 (viii) 其中R5从氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基中选择，R6独立选择自氢、C1-13烷基、芳基和C7-13芳基烷基，R7从氢、C1-13烷基、芳基和C7-13芳基烷基中选择，或任何这种化合物的药用盐；但是当R7为氢时，R6不选择自芳基，并且化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。

  公开号：

  US06335353B1
• 作为产物：
  描述：

  2-甲酰基-3-苄氧基-6-甲基-吡喃-4(1H)-酮 在 4-二甲氨基吡啶 、 sodium chlorite 、 氨基磺酸 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 25.0h， 生成 3-benzyloxy-6-methyl-pyran-4(1H)-one-2-carboxy-(N-methyl)-amide
  参考文献：
  名称：

  Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values

  摘要：

  The synthesis of a range of 2-amido-3-hydroxypyridin-4-ones as bidentate iron(III) chelators with potential for oral administration is described. The pKa values of the ligands together with the stability constants of their iron(III) complexes have been determined. Results indicate that the introduction of an amido substituent at the 2-position leads to an appreciable enhancement of the pFe(3+) values. The ability of these novel 3-hydroxypyridin-4-ones to facilitate the iron excretion in bile was investigated using a Fe-59-ferritin loaded rat model. The optimal effect was observed with the N-methyl amido derivative 15b, which has an associated pFe(3+) value of 21.7, more than two orders of magnitude higher than that of deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) 1a (pFe(3+) = 19.4). Dose response studies suggest that chelators with high pFe(3+) values scavenge iron more effectively at lower doses when compared with simple dialkyl substituted hydroxypyridinones. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00273-x

文献信息

• Orally active iron (III) chelators
  申请人：BTG International Limited

  公开号：US06335353B1

  公开（公告）日：2002-01-01

  A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups —CONH—R5  (i) —CH2NHCO—R5  (ii) —SO2NH—R5  (iii) —CH2NHSO2—R5  (iv) —CR6R6OR7  (v) —CONHCOR5  (viii)  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13 alkyl, aryl and C71-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one.

  提供一种化合物，其为一种新颖的3-羟基吡啶-4-酮化合物，其化学式为I，其中R为氢或在体内代谢中被去除以提供游离羟基化合物的基团，R1为脂肪烃基团或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6芳基氧基或C7-10芳基烷氧基所取代的脂肪烃基团，R3从氢和C1-6烷基中选择；R4从氢、C1-6烷基和如R2所述的基团中选择；其中R2从以下基团中选择：—CONH—R5 (i)—CH2NHCO—R5 (ii)—SO2NH—R5 (iii)—CH2NHSO2—R5 (iv)—CR6R6OR7 (v)—CONHCOR5 (viii) 其中R5从氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基中选择，R6独立选择自氢、C1-13烷基、芳基和C7-13芳基烷基，R7从氢、C1-13烷基、芳基和C7-13芳基烷基中选择，或任何这种化合物的药用盐；但是当R7为氢时，R6不选择自芳基，并且化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。
• [EN] CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES<br/>[FR] DERIVES CYCLOALKYLE DE 3-HYDROXY-4-PYRIDINONES
  申请人：APOTEX INC

  公开号：WO2005049609A1

  公开（公告）日：2005-06-02

  The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula (I); wherein R1 is X with the proviso that R2 is Y; or R1 is T with the proviso that R2 is W; or R1 is X with the proviso that R 2 R 5 N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C1 to C6 alkyl groups. X is C3-C6 cycloalkyl; Y is selected from the group consisting of C1 to C6 cycloalkyl; C1 to C6 alkyl, and C1 to C6 alkyl monosubstituted with a C3-C6 cycloalkyl; T is C1 to C6 alkyl; W is C3-C6 cycloalkyl; R3 is selected from the group consisting of hydrogen and C1 to C6 alkyl; R4 is selected from the group consisting of hydrogen and C1 to C6 alkyl; R5 is selected from the group consisting of hydrogen and C1 to C6 alkyl; and its pharmaceutically acceptable salt thereof. Pharmaceutical compositions of such compounds are useful in the removal of excess body iron from patients with iron overload diseases.

  本发明提供了一种3-羟基-4-吡啶酮的环烷基衍生物，可用于螯合金属离子，如铁。描述了其制备和用途。特别是，本发明涉及化学和生物系统中铁的去除，包括具有式（I）的螯合剂；其中R1是X，但R2是Y；或R1是T，但R2是W；或R1是X，但R2R5N在一起形成从哌啶基，吗啉基，吡咯烷基或哌嗪基中选择的杂环环，其中哌啶基，吗啉基，吡咯烷基或哌嗪基的基团是未取代或用1至3个C1至C6烷基取代。X是C3-C6环烷基；Y选自由C1至C6环烷基；C1至C6烷基和C1至C6烷基单取代的C3-C6环烷基；T是C1至C6烷基；W是C3-C6环烷基；R3选自氢和C1至C6烷基的群；R4选自氢和C1至C6烷基的群；R5选自氢和C1至C6烷基的群；以及其药学上可接受的盐。这些化合物的制药组合物可用于从铁过载病患者中去除体内过量的铁。
• Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention
  申请人：Tam Fat Tim

  公开号：US20070082904A1

  公开（公告）日：2007-04-12

  The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula (I); wherein R 1 is X with the proviso that R 2 is y; or R 1 is T with the proviso that R 2 is W; or R 1 is X with the proviso that R 2 R 5 N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morphoninyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C 1 to C 6 alkyl groups. X is C 3 -C 6 cycloalkyl; Y is selected from the group consisting of C, to C 6 cycloalkyl; C 1 to C 6 alkyl, and C 1 to C 6 alkyl monosubstituted with a C 3 -C 6 cycloalkyl; T is C 1 to C 6 alkyl; W is C 3 -C 6 cycloalkyl; R 3 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 4 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 5 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; and its pharmaceutically acceptable salt thereof. Pharmaceutical compositions of such compounds are useful in the removal of excess body iron from patients with iron overload diseases.

  本发明提供了3-羟基-4-吡啶酮的环烷基衍生物，可用于螯合金属离子，如铁离子。描述了其制备和用途。特别是，本发明涉及化学和生物系统中铁的去除，包括具有式（I）的螯合剂，其中R1为X，但R2为y；或R1为T，但R2为W；或R1为X，但R2R5N在一起形成从哌啶基，吗啉基，吡咯烷基或哌嗪基中选择的杂环环，其中哌啶基，吗啉基，吡咯烷基或哌嗪基的基团是未取代的或用1至3个C1至C6烷基基团取代的。X为C3-C6环烷基；Y选自由C到C6环烷基；C1到C6烷基和C1到C6烷基单取代的C3-C6环烷基；T为C1到C6烷基；W为C3-C6环烷基；R3选自氢和C1到C6烷基的群；R4选自氢和C1到C6烷基的群；R5选自氢和C1到C6烷基的群；以及其药学上可接受的盐。这些化合物的制药组合物可用于治疗铁过载病患者的体内多余铁的去除。
• Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues
  申请人：Tam Fat Tim

  公开号：US20080096886A1

  公开（公告）日：2008-04-24

  The present invention relates to a novel process for the preparation of 1-alkyl or 1-cycloalkyl derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxamide of formula I. The process includes reacting an amine R 2 NH 2 with a compound of formula II in a solution of metal hydroxide in water to give a compound of formula III. Subsequent reaction of the compound of formula III with an acid chloride formation reagent in an inert solvent gives compounds of formula I. The acid chloride formation reagent is selected from oxalyl chloride and dimethylformamide, dimethylchloromethylene-ammonium chloride and thionyl chloride and dimethylformamide. If desired, a compound of formula I where R 5 is hydrogen may be formed when an intermediate substituent is used wherein R 5 is an alcohol protective group removable by catalytic hydrogenation.

  本发明涉及一种新型方法，用于制备式I的1-烷基或1-环烷基的3-羟基-4-氧代-1,4-二氢吡啶-2-羧酰胺衍生物。该方法包括将胺R2NH2与式II的化合物在水中的金属氢氧化物溶液中反应，以得到式III的化合物。随后，在惰性溶剂中使用酸氯化物形成试剂与式III的化合物反应，得到式I的化合物。酸氯化物形成试剂选自草酰氯和二甲基甲酰胺、二甲基氯甲基胺盐酸盐和亚磺酰氯和二甲基甲酰胺。如果需要，当使用中间体取代基时，可以形成式I的化合物，其中R5为氢，R5是通过催化氢化可去除的醇保护基。
• Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
  申请人：Tam Tim Fat

  公开号：US20090170850A1

  公开（公告）日：2009-07-02

  The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula I wherein R 1 is X with the proviso that R 2 is Y; or R 1 is T with the proviso that R 2 is W; or R 1 is X with the proviso that R 2 R 5 N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C 1 to C 6 alkyl groups. X is C 3 -C 6 cycloalkyl; Y is selected from the group consisting of C 1 to C 6 cycloalkyl; C 1 to C 6 alkyl, and C 1 to C 6 alkyl monosubstituted with a C 3 -C 6 cycloalkyl; T is C 1 to C 6 alkyl; W is C 3 -C 6 cycloalkyl; R 3 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 4 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 5 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; and its pharmaceutically acceptable salt thereof. Pharmaceutical compositions of such compounds are useful in the removal of excess body iron from patients with iron overload diseases.

  本发明提供了3-羟基-4-吡啶酮的环烷基衍生物，可用于螯合金属离子，如铁离子。描述了其制备和使用。具体而言，本发明涉及在化学和生物系统中除铁，包括具有式I的螯合剂，其中R1是X，但R2是Y；或R1是T，但R2是W；或R1是X，但R2和R5N在一起形成从哌啶基，吗啡啉基，吡咯烷基或哌嗪基中选择的杂环环，其中哌啶基，吗啡啉基，吡咯烷基或哌嗪基的基团是未取代或用一到三个C1到C6烷基基团取代。X是C3-C6环烷基；Y选自由C1到C6环烷基；C1到C6烷基；和用C3-C6环烷基单取代的C1到C6烷基。T是C1到C6烷基；W是C3-C6环烷基；R3选自氢和C1到C6烷基的群；R4选自氢和C1到C6烷基的群；R5选自氢和C1到C6烷基的群；以及其药学上可接受的盐。这些化合物的制药组合物对于从铁过载病患者中去除过量体内铁非常有用。